<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001494</url>
  </required_header>
  <id_info>
    <org_study_id>M/34273/34</org_study_id>
    <secondary_id>ATTAIN</secondary_id>
    <nct_id>NCT01001494</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the long term bronchodilator efficacy, safety and
      tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD
      patients and the benefits of the product in disease-related health status, COPD symptoms and
      COPD exacerbations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 12 on Treatment</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved at Least a 1-unit Decrease From Baseline in TDI Focal Score at Week 24 on Treatment</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of patients achieving a clinically meaningful improvement (≥1-unit) in Transition Dyspnoea Index (TDI) focal score at Week 24 on Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at Week 24 on Treatment</measure>
    <time_frame>Week 24</time_frame>
    <description>Number of patients who achieved a clinically meaningful improvement (≥4-units) in Saint George Respiratory Questionnaire (SGRQ) total score at week 24 on treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">828</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Aclidinium bromide 200 μg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 200 μg twice-daily via inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aclidininum bromide 400 μg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclidinium bromide 400 μg twice-daily via inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium bromide 200 μg bid</intervention_name>
    <description>Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks</description>
    <arm_group_label>Aclidinium bromide 200 μg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium bromide 400 μg bid</intervention_name>
    <description>Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks</description>
    <arm_group_label>Aclidininum bromide 400 μg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice-daily by inhalation for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female patients aged ≥40 with stable moderate to severe COPD (GOLD
             guidelines).

          -  Post-salbutamol (FEV1) &lt; 80% and ≥30% of predicted normal value and Post-salbutamol
             FEV1/FVC &lt; 70%.

          -  Current or ex-smokers of ≥10 pack-years.

        Exclusion Criteria:

          -  Patients with no history or current diagnosis of asthma.

          -  No evidence of an exacerbation within 6 weeks prior to the screening visit.

          -  No evidence of clinically significant respiratory and/or cardiovascular conditions or
             laboratory abnormalities.

          -  No contraindication to use of anticholinergic drugs such as known symptomatic
             prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Garcia, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Benesov</city>
        <zip>256 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#9</name>
      <address>
        <city>Jaromer</city>
        <zip>55 101</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Liberec</city>
        <zip>460 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>Lovosice</city>
        <zip>410 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Neratovice</city>
        <zip>277 11</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#11</name>
      <address>
        <city>Praha</city>
        <zip>158 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Praha</city>
        <zip>158 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#12</name>
      <address>
        <city>Praha</city>
        <zip>163 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#7</name>
      <address>
        <city>Praha</city>
        <zip>169 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#10</name>
      <address>
        <city>Strakonice</city>
        <zip>386 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Clermont-Ferrand Cedex</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#8</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#9</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#14</name>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site#7</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#12</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#13</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#15</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#5</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site#16</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#18</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#10</name>
      <address>
        <city>Koln</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#11</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site#2</name>
      <address>
        <city>Rüdersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#13</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Budapest</city>
        <zip>1046</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>Budapest</city>
        <zip>1529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#5</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#7</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#10</name>
      <address>
        <city>Dunaüjváros</city>
        <zip>2400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#9</name>
      <address>
        <city>Mátraháza</city>
        <zip>3233</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#12</name>
      <address>
        <city>Pécs</city>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#11</name>
      <address>
        <city>Ráckeve</city>
        <zip>2300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Százhalombatta</city>
        <zip>2440</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#8</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Cagliari</city>
        <zip>09126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#10</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#8</name>
      <address>
        <city>Cusco</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#12</name>
      <address>
        <city>Białystok</city>
        <zip>15-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#9</name>
      <address>
        <city>Białystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#19</name>
      <address>
        <city>Elblag</city>
        <zip>82-307</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#18</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#20</name>
      <address>
        <city>Ilawa</city>
        <zip>14-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#7</name>
      <address>
        <city>Lodz</city>
        <zip>90-430</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Lodz</city>
        <zip>91-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#8</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#24</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#5</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#21</name>
      <address>
        <city>Poznan</city>
        <zip>60-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#16</name>
      <address>
        <city>Poznan</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site#11</name>
      <address>
        <city>Proszowice</city>
        <zip>32-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>Ruda Slaska</city>
        <zip>41-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#13</name>
      <address>
        <city>Rudka</city>
        <zip>05-320</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Sopot</city>
        <zip>81-741</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#14</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#15</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#25</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#23</name>
      <address>
        <city>Wilkowice-Bystra</city>
        <zip>43-365</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Site#10</name>
      <address>
        <city>Wrocław</city>
        <zip>50-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#7</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620219 / 620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#5</name>
      <address>
        <city>Kazan</city>
        <zip>420015/420103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>Moscow</city>
        <zip>115446</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#14</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Moscow</city>
        <zip>127018/127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#13</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#10</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197089/197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#8</name>
      <address>
        <city>Tomsk</city>
        <zip>634050/634034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#12</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#8</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#11</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#10</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#12</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#15</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#9</name>
      <address>
        <city>George</city>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#5</name>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#14</name>
      <address>
        <city>Pretoria</city>
        <zip>0081</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Pretoria</city>
        <zip>181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#8</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#7</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#5</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Donetsk</city>
        <zip>83099</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Kharkiv</city>
        <zip>61001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#7</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#5</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69118</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Mexico</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.almirall.com/webcorp2/cda/ImD_04_02.jsp</url>
    <description>Almirall Corporate Website</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2009</study_first_posted>
  <results_first_submitted>August 14, 2012</results_first_submitted>
  <results_first_submitted_qc>August 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 17, 2012</results_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>antimuscarinic</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 103 sites (100/103 randomised patients), 10 sites in the Czech Republic, 5 in France, 17 in Germany, 13 in Hungary, 3 in Italy, 1 in Peru, 21 in Poland, 10 in the Russian Federation, 5 in Spain, 13 in South Africa and 5 in the Ukraine. The first patient was screened in Oct 2009 and the last patient visit was in Nov 2010.</recruitment_details>
      <pre_assignment_details>Patients fulfilling inclusion/exclusion criteria at the time of the Screening Visit were entered into a run-in period of 14±3 days to assess patient’s disease stability.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aclidinium Bromide 200 μg Bid</title>
          <description>Aclidinium bromide 200 μg twice-daily via inhalation</description>
        </group>
        <group group_id="P2">
          <title>Aclidinium Bromide 400 μg Bid</title>
          <description>Aclidinium bromide 400 μg twice-daily via inhalation</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo via inhalation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="277">280 patients were randomized, but baseline data was missing from 3 patients in one center</participants>
                <participants group_id="P2" count="269">272 patients were randomized, but baseline data was missing from 3 patients in one center</participants>
                <participants group_id="P3" count="273">276 patients were randomized, but baseline data was missing from 3 patients in one center</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
                <participants group_id="P2" count="252"/>
                <participants group_id="P3" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>COPD exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aclidinium Bromide 200 μg Bid</title>
          <description>Aclidinium bromide 200 μg twice-daily via inhalation</description>
        </group>
        <group group_id="B2">
          <title>Aclidinium Bromide 400 μg Bid</title>
          <description>Aclidinium bromide 400 μg twice-daily via inhalation</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo via inhalation</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="277"/>
            <count group_id="B2" value="269"/>
            <count group_id="B3" value="273"/>
            <count group_id="B4" value="819"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="509"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="7.8"/>
                    <measurement group_id="B2" value="62.9" spread="8.4"/>
                    <measurement group_id="B3" value="62.0" spread="8.0"/>
                    <measurement group_id="B4" value="62.4" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment</title>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium Bromide 200 μg Bid</title>
            <description>Aclidinium bromide 200 μg twice-daily via inhalation</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium Bromide 400 μg Bid</title>
            <description>Aclidinium bromide 400 μg twice-daily via inhalation</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo via inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment</title>
          <population>Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.026" spread="0.016"/>
                    <measurement group_id="O2" value="0.055" spread="0.016"/>
                    <measurement group_id="O3" value="-0.073" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 12 on Treatment</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium Bromide 200 μg Bid</title>
            <description>Aclidinium bromide 200 μg twice-daily via inhalation</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium Bromide 400 μg Bid</title>
            <description>Aclidinium bromide 400 μg twice-daily via inhalation</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo via inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 12 on Treatment</title>
          <population>Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" spread="0.014"/>
                    <measurement group_id="O2" value="0.058" spread="0.015"/>
                    <measurement group_id="O3" value="-0.047" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment</title>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium Bromide 200 μg Bid</title>
            <description>Aclidinium bromide 200 μg twice-daily via inhalation</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium Bromide 400 μg Bid</title>
            <description>Aclidinium bromide 400 μg twice-daily via inhalation</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo via inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment</title>
          <population>Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.206" spread="0.017"/>
                    <measurement group_id="O2" value="0.231" spread="0.017"/>
                    <measurement group_id="O3" value="0.022" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved at Least a 1-unit Decrease From Baseline in TDI Focal Score at Week 24 on Treatment</title>
        <description>Number of patients achieving a clinically meaningful improvement (≥1-unit) in Transition Dyspnoea Index (TDI) focal score at Week 24 on Treatment</description>
        <time_frame>Week 24</time_frame>
        <population>Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium Bromide 200 μg Bid</title>
            <description>Aclidinium bromide 200 μg twice-daily via inhalation</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium Bromide 400 μg Bid</title>
            <description>Aclidinium bromide 400 μg twice-daily via inhalation</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo via inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved at Least a 1-unit Decrease From Baseline in TDI Focal Score at Week 24 on Treatment</title>
          <description>Number of patients achieving a clinically meaningful improvement (≥1-unit) in Transition Dyspnoea Index (TDI) focal score at Week 24 on Treatment</description>
          <population>Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (% Patients with a 1-unit decrease)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="56.9"/>
                    <measurement group_id="O3" value="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (% Patients with a 1-unit decrease)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="43.1"/>
                    <measurement group_id="O3" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at Week 24 on Treatment</title>
        <description>Number of patients who achieved a clinically meaningful improvement (≥4-units) in Saint George Respiratory Questionnaire (SGRQ) total score at week 24 on treatment</description>
        <time_frame>Week 24</time_frame>
        <population>Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aclidinium Bromide 200 μg Bid</title>
            <description>Aclidinium bromide 200 μg twice-daily via inhalation</description>
          </group>
          <group group_id="O2">
            <title>Aclidinium Bromide 400 μg Bid</title>
            <description>Aclidinium bromide 400 μg twice-daily via inhalation</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo via inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at Week 24 on Treatment</title>
          <description>Number of patients who achieved a clinically meaningful improvement (≥4-units) in Saint George Respiratory Questionnaire (SGRQ) total score at week 24 on treatment</description>
          <population>Intention-to-treat (ITT) population: all randomised patients who took at least one dose of Investigational Medicinal Product and who had a baseline and at least 1 post-baseline FEV1 assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (% Patients with 4-unit decrease)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0"/>
                    <measurement group_id="O2" value="57.3"/>
                    <measurement group_id="O3" value="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (% Patients with 4-unit decrease)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0"/>
                    <measurement group_id="O2" value="42.8"/>
                    <measurement group_id="O3" value="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aclidinium Bromide 200 μg Bid</title>
          <description>Aclidinium bromide 200 μg twice-daily via inhalation</description>
        </group>
        <group group_id="E2">
          <title>Aclidinium Bromide 400 μg Bid</title>
          <description>Aclidinium bromide 400 μg twice-daily via inhalation</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo via inhalation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Left vetricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Mixed deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament ruptures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Invertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder transitional cell carcinoma stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pancreatic neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Aortis stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Subclavian atery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructivce pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="269"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All the information related to this clinical trial is considered strictly confidential and is the property of Almirall. This information will not be given to a third party without the written consent of Almirall. Publication and/or presentation, whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and Almirall.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical</name_or_title>
      <organization>Study Information Center</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

